| Document |
Document Title |
|
WO/2023/235982A1 |
Provided herein are antibodies that specifically target integrin beta-2 and compositions comprising such antibodies for therapeutic and diagnostic applications. The antibodies comprise an integrin beta-2 binding domain comprising a heavy...
|
|
WO/2023/235949A1 |
The present invention relates to a dental/medical device consisting of an absorbable synthetic membrane, preferably white to gray in color, comprising poly(dioxanone) and optionally graphene and stem cells, to be used in guided tissue re...
|
|
WO/2023/239672A1 |
Provided herein are methods of co-culturing a myogenic cell with a support cell to increase myotube formation from the myogenic cells. For example, provided herein is a method comprising co-culturing a myogenic cell with a support cell w...
|
|
WO/2023/237770A1 |
The present invention relates to a method for culturing culture cells requiring a supply of iron, comprising a step of culturing cells to be cultured in a culture medium, the antioxidant capacity of which is higher than or equal to the a...
|
|
WO/2023/238125A1 |
Provided herein are compositions comprising T cells expressing a recombinant virus-specific T cell receptor (rTCR-V) specific for a viral antigen restricted by a predetermined HLA type, rTCR-Vs, methods for preparing them, their use for ...
|
|
WO/2023/239483A1 |
The present disclosure provides a method of producing a non-human mammalian animal model comprising human neural tissue, the method comprising introducing a first human neural organoid into a central nervous system location of a newborn ...
|
|
WO/2023/240147A1 |
Disclosed herein are engineered iPSCs and cells derived therefrom that express CD16 variants and NKG2D. Also, the engineered iPSCs and cells derived therefrom can express a chimeric antigen receptor. Additionally, provided herein are pol...
|
|
WO/2023/239266A1 |
The present invention relates to the field of biotechnology and medicine, in particular to a monoclonal antibody or antigen-binding fragment thereof that specifically binds to BCMA. The invention further relates to nucleic acids encoding...
|
|
WO/2023/239928A1 |
This disclosure provides a technology for adapting host cells to maximize production of viral vectors and particles. Cell hybrids are formed from parental cell lines, and divided or cloned into multiple aliquots for testing. Aliquots are...
|
|
WO/2023/237785A1 |
This invention relates to methods for producing immune cells expressing a therapeutic antigen receptor. An immune cell is provided that comprises a heterologous expression cassette. The heterologous expression cassette comprises (a) a co...
|
|
WO/2023/237774A1 |
The present invention relates to a fusion protein that provides for maintenance of regulatory T-cells that are polyclonal, e.g. natural isolated antigen-specific Treg cells, and/or Treg cells generated by introduction of a nucleic acid c...
|
|
WO/2023/240053A2 |
Disclosed herein are lung progenitor cells that are in the form of lung organoids and methods of generating the lung progenitor cells. The lung organoids can be an important resource for treating lung disorders and injuries, studies in h...
|
|
WO/2023/235971A1 |
Provided herein are antibodies to active integrin beta-2 and compositions comprising such antibodies for the treatment of a cancer, e.g., acute myeloid leukemia.
|
|
WO/2023/236954A1 |
The present invention relates to a PD-1 variant and the use thereof. Specifically, the PD-1 variant of the present invention can bind to PD-L1 with high affinity, but does not bind to one or more anti-PD-1 monoclonal antibodies, and pref...
|
|
WO/2023/238074A1 |
Provided herein are methods and related compositions for enhancing or enhanced partial reprogramming of target cells in a subject in need thereof (e.g., a human subject suffering from or at risk of a disease), the method comprising admin...
|
|
WO/2023/240152A1 |
Provided herein are methods of engineering a cell line for reduced dependence on exogenous growth factor(s). In some embodiments, the method includes introducing into a cell one or more of: a polynucleotide comprising a coding sequence o...
|
|
WO/2023/240153A1 |
The present disclosure is directed to a mammalian cell comprising an arthropod chemosensory receptor and its uses in methods of identifying repellents and attractants or traps for use in an arthropod control article comprising an arthrop...
|
|
WO/2023/240143A1 |
The present disclosure is directed to methods of preparing genetically engineered lymphocytes. In addition, methods of using the genetically engineered lymphocytes in T cell therapy for cancers are also disclosed.
|
|
WO/2023/237764A1 |
The invention provides an in-vitro or ex-vivo method for transiently modifying immune cells in a closed processing system comprising the steps: (i) providing immune cells from a biological liquid and/or from a resected tumor from a patie...
|
|
WO/2023/234320A1 |
The purpose of the present invention is to provide: a method for producing a genetically modified pig having, introduced selectively to a tissue or organ, a gene group for expressing a specific functional protein in the tissue or organ; ...
|
|
WO/2023/235819A1 |
Recombinant receptors with a binding domain that binds B cell activation factor receptor (BAFF-R) are disclosed. Recombinant receptors include chimeric antigen receptors (CAR) having an anti-BAFF-R binding domain, a transmembrane domain,...
|
|
WO/2023/232961A1 |
Herein is reported a modified mammalian cell wherein the transcriptional activity of a procollagen-lysine,2-oxoglutarate 5-dioxygenases (PLOD) has been eliminated.
|
|
WO/2023/234319A1 |
Provided are a method for producing a transgenic pig into which a gene group for expressing specific functional proteins in a tissue or an organ is introduced selectively into this tissue or organ, somatic cell cloning materials used the...
|
|
WO/2023/232111A1 |
The present disclosure provides a MAGE-A1-specific TCR and use thereof, and specifically relates to a TCR modified to improve binding affinity, a nucleic acid encoding same, a vector comprising the nucleic acid of the present invention, ...
|
|
WO/2023/235828A1 |
Provided are methods to increase the nephron yield and control over nephron locations in kidney organoids and kidney replacement tissues; the methods achieve spatiotemporal control over the mechanical microenvironment to engineer favorab...
|
|
WO/2023/234421A1 |
The present invention addresses the problem of providing a cartilage cell sheet obtained using pluripotent stem cells as a cell source. Said problem is solved by a cartilage-repairing cell sheet that is formed from a cultured product of ...
|
|
WO/2023/232099A1 |
A method for obtaining vesicles, and further provided is a method for producing vesicles. The method comprises: enabling cells to produce the vesicles by means of the action of a negative pressure. After the cells are subjected to the ne...
|
|
WO/2023/232777A1 |
Disclosed herein are engineered progenitor cells and methods of using the same. Also disclosed herein are engineered cells differentiated from engineered progenitor cells of the present disclosure. Also disclosed herein are methods of tr...
|
|
WO/2023/234170A1 |
An embodiment of the present invention pertains to a culture vessel in which enough oxygen for the growth of cells or the like is supplied from a bottom section of the culture vessel having cultured matter such as cells adhered thereto, ...
|
|
WO/2023/230729A1 |
The present description relates to synthetic antigen receptors for use with covalent immune recruiters (CIRs) comprising an donor moiety, a covalent binding group, and a target binding domain (TBD), the synthetic antigen receptor compris...
|
|
WO/2023/231086A1 |
The present invention relates to uses of DDUP for tumor drug resistance detection, for treatment, and as prognosis molecular targets. DDUP can regulate and control DNA damage and/or repair DNA damage, is remarkably related to the platinu...
|
|
WO/2023/234419A1 |
Provided is, for example, a DNA methyltransferase that can recognize and methylate a short context other than a CG dinucleotide sequence in which endogenous methylation occurs, the short context being comparable to the CG dinucleotide se...
|
|
WO/2023/137235A9 |
The present disclosure addresses cell type heterogeneity during differentiation of human pluripotent stem cells into islet cells by shifting cell identity from alpha cells to beta cells. More specially, the present disclosure provides a ...
|
|
WO/2023/235879A1 |
Provided in this disclosure are methods of producing a fertilized embryo comprising a genomic edit and engineered cells and organisms therefrom. In certain aspects, engineered cells can be created utilizing AAVs and CRISPR/Cas systems.
|
|
WO/2023/235132A1 |
The present disclosure is directed to various compositions that include one or more energy source components; one or more pH buffers; one or more salts; and one or more stabilizing agents and one or more cell types.
|
|
WO/2023/234461A1 |
The present invention relates to a scFv that specifically binds to EGFRvIII, which is a mutant EGFR, a CAR comprising same, and a CAR-T cell expressing same. According to the present invention, it has been confirmed that CAR-T cells expr...
|
|
WO/2023/233827A1 |
The present invention acquires a hologram image of an object in a state in which the object is accommodated in a recess in a container, a bottom surface of the recess being curved. A phase image is generated from the hologram image. Proc...
|
|
WO/2023/234330A1 |
The present invention addresses the problem of providing an EGFR CAR-T cell which is expected to be effective against a tumor in which an EGFR is expressed. The present invention provides: a polynucleotide encoding a chimeric antigen rec...
|
|
WO/2023/202672A9 |
The present disclosure provides an isolated monoclonal antibody that specifically binds human SIRPα, or an antigen-binding portion thereof. A nucleic acid molecule encoding the antibody or the antigen-binding portion thereof, an express...
|
|
WO/2023/233002A1 |
The invention provides an in vitro method of producing a fused tissue culture with at least three different tissues comprising selecting a spatial shape for attaching the at least three different tissues to each other, placing the at lea...
|
|
WO/2023/234416A1 |
The present invention relates to a technology for facile chemical modification of only one heavy chain in an antibody structural unit (immunoglobulin unit comprising two heavy chains and optionally two light chains). More specifically, t...
|
|
WO/2023/231834A1 |
Provided are a hydrogel-based cell encapsulation method, a cell-encapsulating polymerized microgel prepared therefrom, and a kit thereof. The hydrogel-based cell encapsulation method can include: (a) providing a cell suspension as an aqu...
|
|
WO/2023/233176A1 |
The invention relates to human induced pluripotent stem cell (hiPSC) expressing a reporter, in particular 1RFP720. The hiPSC and cells differentiated thereof are useful for real-time imaging and tracking of transplanted cells in preclini...
|
|
WO/2023/235479A1 |
Disclosed herein are methods for treatment of a mesothelin (MSLN)-expressing cancer in a human subject comprising administration of, e.g., a plurality of anti-MSLN T cell receptor fusion protein (TFP)– expressing T cells that further c...
|
|
WO/2023/288283A9 |
The present disclosures relates to methods of use to the use of interleukin-2 (IL2) muteins, pharmaceutical formulations thereof, methods useful in the treatment of human disease in combination with adoptive cell therapy. In particular, ...
|
|
WO/2023/234409A1 |
The present invention provides: a composition which is for increasing the efficiency of genome editing with a single-strand-form editing polynucleotide that is capable of modifying a target site in a double-stranded genome DNA, the compo...
|
|
WO/2023/232750A1 |
The present invention pertains to cell culture protocols and particularly provides a method for obtaining Invariant Natural Killer T (iNKT) cells. The method according to the present invention particularly comprises culturing peripheral ...
|
|
WO/2023/233394A1 |
The present invention relates to a fibrillar hydrogel comprising an aqueous solution and substantially aligned fibrils composed of collagen and at least one proteoglycan, having viscoelastic characteristics enabling its use in a wide ran...
|
|
WO/2023/232003A1 |
The present invention relates to an anti-HBsAg antibody. In particular, the present invention relates to a tetravalent antibody bound to HBsAg and a corresponding heavy chain antibody. The present invention further relates to a pharmaceu...
|
|
WO/2023/233155A1 |
The invention provides the use of micro-scale three-dimensional objects on a surface, to influence the extent to which macrophage attachment occurs at the surface and/or the phenotype of macrophage that attaches to the surface. The inven...
|
